Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the most expensive surprises rarely arrive as a thunderclap. They arrive as a filing.
A Paragraph IV challenge can look like a legal event on pape…

Your drug patent isn’t “one number.” In the GCC, it’s a moving target. Here’s how to know exactly how long it lasts.
If you’re a brand team, a generic competitor, or an investor underwriting pipeline timelines, you already know the uncomfortable truth:…

Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor isn’t “inventing” anything. They’re extending.
In pharma, the most consequential moves rarely look like breakthroughs. They look like paperwork—amendments, new claims, fresh filings, and carefully timed patent strategies that keep a p…

Biopharma teams don’t lose deals because they lack ambition. They lose because they’re pitching the wrong story at the wrong time.
In licensing, partnering, and commercial strategy, timing is everything. Yet too many BizDev and packaging teams still op…

OpenAI’s “GPT for Life Sciences” is getting the hype cycle treatment. But the real question isn’t whether the model can generate text—it’s what it changes in the drug development pipeline when the novelty wears off.
Because in pharma, the bottleneck ra…

Most biosimilar strategies fail for one reason: they show up too late.
In biosimilars, timing isn’t a “nice-to-have.” It’s the whole game.
Right now, manufacturers are making equipment and capacity decisions—often months (or longer) before the market a…

Drug patent protection in Europe: how long it lasts—and where it quietly breaks down
Most people think European drug patents are a simple clock: file today, expire later. In reality, the timeline is a patchwork—extended by legal mechanisms, interrupted…

Drug discovery timelines are getting longer—until they aren’t.
For years, the industry has treated time like a fixed constraint: target identification, assay development, data cleaning, trial design, regulatory documentation—each step a gate that takes…

The “Patent Expiration Cliff” Isn’t a Cliff—It’s a Calendar Problem. Here’s How Commercial Market Access Teams Can Stop Getting Blindsided.
If you work in commercial market access, you’ve probably felt it: the sudden scramble when a blockbuster’s exclu…